The stock should re-rate on the strategic clarity and cash infusion, but the deal is not yet binding—monitor for physician partner approval and HSR clearance. The Q2 2026 earnings call on August 10 will be a key catalyst for further details on the financial impact and capital allocation plans for the proceeds.
Price Chart
Executive Summary
Surgery Partners announced an agreement to sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for total consideration of approximately $795 million. The transaction values the combined facilities at approximately $1.15 billion. The deal is subject to physician partner approvals, HSR waiting period expiration, and other customary closing conditions, with an expected close 'in the coming months.' The company reaffirmed its 2026 revenue guidance of $3.35B-$3.45B and Adjusted EBITDA of at least $530M, excluding the transaction's impact. This is a significant portfolio optimization event, simplifying operations and providing substantial cash proceeds for debt reduction or reinvestment into the higher-growth ASC business, but the deal is not yet fully binding and carries execution risk.
Key Financial Metrics
Key Facts
- Surgery Partners to sell Idaho Falls facilities to Intermountain Health for ~$795M in total consideration.
- Combined facilities valued at ~$1.15B.
- Transaction is a key step in portfolio optimization, sharpening focus on ambulatory surgery centers.
- Deal is subject to physician member/board approvals, HSR clearance, and other regulatory/third-party consents.
- Company reaffirms 2026 guidance (revenue $3.35B-$3.45B, Adj. EBITDA ≥$530M) excluding the transaction.
- Signature pages placed into escrow; binding agreements not yet fully executed.
- Outside closing date is 60 days after release from escrow, subject to extension.
- Physician ownership of Mountain View Hospital will remain unchanged.
Financial Impact
Total consideration of ~$795M to Surgery Partners, subject to customary purchase price adjustments for indebtedness, working capital, and transaction expenses. Final net cash proceeds not yet estimable.
Risk Factors
- Physician member/board approvals may not be obtained, preventing the deal from closing.
- Regulatory approvals (HSR, other) could be delayed or impose conditions.
- Final net cash proceeds are subject to adjustments and may be lower than headline ~$795M.
- Execution risk in redeploying proceeds into ASC growth or debt reduction.
- Potential litigation or diversion of management attention during the pendency of the transaction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001638833-26-000069 |
| Document: a101-exhibit991pressrelease.htm | 0001638833-26-000069 |
| Document: 0001638833-26-000069-index-headers.html | 0001638833-26-000069 |
| Document: 0001638833-26-000069-index.html | 0001638833-26-000069 |
| Document: 0001638833-26-000069.txt | 0001638833-26-000069 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEFA14A | $23.32 | awaiting T+5 | — | $23.25 (−0.30%) |
Oct 26, 2026 today | SC 13D/A | — | awaiting T+5 | — | — |
Oct 26, 2026 today | DEFA14A | — | awaiting T+5 | — | — |
Oct 26, 2026 today | 8-K | — | awaiting T+5 | — | — |
Oct 13, 2026 13d ago | SC 13G | $14.83 $15.40 | ▲ +3.84% | ▲ +3.39% | $23.25 (+56.78%) |
Sep 17, 2026 5w ago | 8-K | $13.35 $14.20 | ▲ +6.37% | ▲ +5.77% | $23.25 (+74.16%) |
Sep 17, 2026 5w ago | Press Release | $13.35 $14.20 | ▲ +6.37% | ▲ +5.52% | $23.25 (+74.16%) |
Aug 20, 2026 9w ago | Insider Buy | $14.52 $13.69 | ▼ −5.72% | ▼ −6.19% | $23.25 (+60.12%) |
Aug 10, 2026 11w ago | 8-K | $15.95 $14.36 | ▼ −9.97% | ▼ −9.92% | $23.25 (+45.77%) |
Aug 10, 2026 11w ago | Press Release | $15.95 $14.36 | ▼ −9.97% | ▼ −9.92% | $23.25 (+45.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers